Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

Table 1

Baseline characteristics of real-world patient population (), displayed separately for patients who met the eligibility criteria for the ORATORIO clinical trial and patients who did not meet the eligibility criteria.

	Real world			ORATORIO^a
	ORATORIO not eligible; ()	ORATORIO eligible; ()	Total; ()	Ocrelizumab; ()
Age (yr)
Mean (SD)	54.90 (8.03)	49.55 (3.04)	52.09 (6.42)	44.7 (7.9)
Median (range)	56.50 (37-67)	49.00 (46-54)	53.00 (37-67)	46.0 (20-56)
Female sex—no. (%)	5 (50.0)	9 (81.8)	14 (66.7)	237 (48.6)
Time since onset of MS symptoms (yr)
Mean (SD)	6.76 (4.16)	7.42 (4.70)	7.11 (4.35)	6.7 (4.0)
Median (range)	6.04 (.63-12.47)	5.66 (1.95-14.53)	5.95 (.63-14.53)	6.0 (1.1-32.9)
Time since diagnosis of PPMS (yr)
Mean (SD)	4.45 (4.42)	5.32 (4.39)	4.9 (4.31)	2.9 (3.2)
Median (range)	3.30 (.23-12.47)	3.75 (.21-14.53)	3.75 (.21-14.53)	1.6 (.1-16.8)
No previous use of disease-modifying therapy—no. (%)	9 (90.0)	11 (100)	20 (95.2)	433 (88.7)
If yes: dimethyl fumarate	1 (10.0)	0 (0)	1 (4.8)	NA
Score on EDSS
Mean (SD)	4.9 (.99)	5.72 (1.15)	5.33 (1.13)	4.7 (1.2)
Median (range)	4.75 (3.5-6.5)	6.50 (3.5-6.5)	6.0 (3.5-6.5)	4.5 (2.5-7.0)

^aORATORIO data were adapted from Montalban et al. [12].